InflaRx N.V. (IFRX) Reports Q2 Loss, Misses Revenue Estimates

Stock Information for InflaRx N.V.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About InflaRx N.V.

InflaRx Announces International Nonproprietary Name of "Izicopan" for INF904
InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU)
InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria
InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
InflaRx Announces Participation in September Investor Conferences
InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update
InflaRx to Report Second Quarter 2025 Results on August 7, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.